Can Immutep Limited convert orphan designation into a credible late-stage oncology program?
FDA orphan drug designation gives Immutep Limited a new sarcoma pathway. Find out why eftilagimod alfa could reshape its oncology strategy.
Why Anixa Biosciences’ Phase 2 breast cancer vaccine push matters more than the manufacturing deal itself
Anixa Biosciences is advancing its breast cancer vaccine toward Phase 2 after positive Phase 1 data. Read what this means for oncology watchers.
How Agilent’s PD-L1 companion diagnostic now shapes pembrolizumab access in esophageal carcinoma
FDA approves Agilent’s PD-L1 IHC 22C3 pharmDx for esophageal and GEJ carcinoma, marking the eighth companion diagnostic indication alongside pembrolizumab. Read the analysis.
Can Synthekine’s STK-012 overcome immunotherapy resistance in first-line NSCLC patients?
Can STK-012 overcome immunotherapy resistance in lung cancer? Explore AACR 2026 data and what it means for IL-2 precision therapies.
How Citius Oncology’s LYMPHIR program reflects a broader shift in immuno-oncology strategy
Citius Oncology reports early LYMPHIR plus pembrolizumab data in gynecologic cancers. Explore what the study reveals about the future of immuno-oncology strategies.
How Adela’s tissue-free ctDNA methylation test could reshape monitoring of immunotherapy outcomes
Adela’s methylome blood test may help detect immunotherapy response earlier in cancer care. Discover what the latest study reveals for clinicians and diagnostics markets.
Merck strengthens its women’s oncology position with KEYNOTE-B96 overall survival results
KEYNOTE-B96 shows overall survival gains for pembrolizumab in platinum-resistant ovarian cancer. Find out why this trial could reshape treatment strategy.
Merck’s KEYTRUDA plus WELIREG cuts recurrence risk in Phase 3 LITESPARK-022 trial for adjuvant clear cell renal cell carcinoma
KEYTRUDA plus belzutifan cuts recurrence risk in adjuvant RCC. Explore what LITESPARK-022 changes for kidney cancer treatment.
Moderna and Merck’s mRNA-4157 combo shows durable benefit in resected high-risk melanoma
Moderna, Inc. and Merck have reported five-year follow-up results from the Phase 2b KEYNOTE-942 study evaluating intismeran autogene (mRNA-4157 or V940), an investigational individualized mRNA-based neoantigen therapy, in combination with pembrolizumab (KEYTRUDA) in patients with resected high-risk stage III or IV melanoma. The combination demonstrated a 49 percent reduction in the risk of recurrence or […]
PADCEV plus Keytruda meets survival endpoints in cisplatin-eligible bladder cancer patients
Astellas Pharma Inc. and Pfizer Inc. have announced that their antibody-drug conjugate PADCEV (enfortumab vedotin), in combination with the PD-1 inhibitor pembrolizumab (marketed as Keytruda by Merck), met key survival endpoints in the Phase 3 EV-304 trial. In cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC), the combination significantly improved both event-free survival and overall survival […]